review Open AccessTop 1% cited
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease
Biochemical Pharmacology · 2007 · Vol. 75(2) · pp. 346–359
J.D. Raffetto(VA Boston Healthcare System)Raouf A. Khalil✉(Brigham and Women's Hospital)
Blood Coagulation and Thrombosis MechanismsProtease and Inhibitor MechanismsCardiovascular Issues in PregnancyMatrix metalloproteinaseGelatinasesAngiogenesisVascular smooth muscleExtracellular matrixProteolytic enzymesMMP1MedicineImmunologyCell biology
MeSH terms
AnimalsBlood VesselsFemaleHumansHypertensionPre-EclampsiaPregnancyVaricose VeinsVascular DiseasesAortic Aneurysm, AbdominalNeovascularization, PhysiologicTissue Inhibitor of MetalloproteinasesMatrix MetalloproteinasesCoronary RestenosisAtherosclerosis
Citations
732
FWCI
22.09
field-weighted impact
References
123
Percentile
100%
vs. same field & year
Citations per year
Cited by
Animal models of atherosclerosis
European Journal of Pharmacology · 2017 · 515 citations
References
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques.
Journal of Clinical Investigation · 1994 · 2,527 citations
Metalloproteinase inhibitors: biological actions and therapeutic opportunities
Journal of Cell Science · 2002 · 1,164 citations
Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases
Circulation Research · 2003 · 4,481 citations
Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis
Circulation Research · 2002 · 1,519 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.